Ross Morton’s Nodenza Venture Partners Named Top 3 Finalist for the Allocator One American Breakout Fund Award

Life Sciences VC firm recognized as top three at the Alpha Summit Americas

SAN FRANCISCO, May 28, 2026 — Ross Morton, Founder and Managing Partner of Nodenza Venture Partners (“Nodenza”), today announced that the firm has been named a Top 3 finalist for the Allocator One American Breakout Fund Award. Allocator 1 see a field of over 1,000 funds per year and selected Nodenza for recognition at the Alpha Summit Americas in San Francisco.

The Allocator One American Breakout Fund Award recognizes emerging venture capital fund managers in the United States demonstrating exceptional investment performance, institutional-grade transparency, and a differentiated approach to capital allocation. The award was presented at the Alpha Summit Americas — an exclusive, invitation-only gathering of leading global investors, emerging fund managers, and founders, across private equity, venture capital, and emerging asset classes.

“Being named top three breakout fund is a strong validation of our approach,” said Ross Morton, Managing Partner of Nodenza. “We remain focused on backing Life Sciences companies that can deliver real outcomes for patients and outstanding returns for our investors.”

A Thesis Built on Operator Experience

Nodenza specializes in clinical proof-of-concept and product launch Life Sciences companies — the stages of the development cycle with the highest value inflection for the shortest time. The firm’s bi-modal strategy targets two distinct opportunity sets: clinical stage companies advancing new treatment modalities from active IND through Phase 2, and commercial-stage companies transitioning from scientific to commercial growth.

The Nodenza team brings a rare depth of operating and investment experience to each investment decision, with a combined track record — built across the team’s prior careers in Life Sciences — spanning $2.7 billion in exits, more than 20 regulatory approvals, and 40 product launches across 60 countries.

What distinguishes Nodenza is how it thinks about returns. The firm draws a direct line from clinical benefit to patient outcomes to financial value. One example from the team’s prior work: Erwinase, developed for children with hypersensitive acute lymphoblastic leukemia, saved the lives of approximately 600 children a year when it launched in the United States. Another: the McGrath Laryngoscope, which helps 50,000 patients a year avoid brain damage during intubation. These are the kinds of technologies Nodenza was built to back.

Ross Morton founded Nodenza following a personal journey through Life Sciences that began not in a boardroom, but as a patient. Diagnosed with Crohn’s disease at the age of 16, he went on to build and sell two biotech companies in the United Kingdom before relocating to the United States to invest in the technologies he wished had existed when he was ill. That perspective — as patient, operator, and investor — shapes every capital allocation decision Nodenza makes.

Institutional-Grade Transparency

Nodenza’s selection by Allocator One reflects not only investment performance but the firm’s commitment to the operational standards institutional allocators require. The Allocator One platform evaluates funds on their ability to provide comprehensive, consistent, and verifiable data for deep due diligence — not returns alone.

“Platforms like Allocator One are raising the bar for the entire industry,” Morton added. “Managers who have a genuine edge and nothing to hide welcome that scrutiny.”